Chemiesynth (Vapi) Ltd (539230)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 4 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 6 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Chemiesynth (Vapi) Ltd reported Q2 FY27 results on 4 Nov 2026: revenue ₹5.3 Cr (-22.6% year on year, +26.8% on the previous quarter), and net profit ₹-0.2 Cr (a smaller loss than a year earlier); the operating margin was 8.0%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹5.3 | -22.6% | +26.8% |
| செயல்பாட்டு லாபம் | ₹0.4 | +123.1% | +992.5% |
| நிகர லாபம் | ₹-0.2 | நஷ்டம் குறைந்தது | நஷ்டம் குறைந்தது |
| EPS (₹) | -0.52 | நஷ்டம் குறைந்தது | நஷ்டம் குறைந்தது |
| செயல்பாட்டு லாப வரம்பு | 8.0% | — | — |
- செயல்பாட்டு லாப வரம்பு 520 bps YoY அதிகரித்தது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Chemiesynth (Vapi) Limited held its Board of Directors meeting on November 4, 2026, approving the unaudited financial results for the quarter and half year ended September 30, 2026. The meeting commenced at 2:00 p.m. and concluded at 2:50 p.m. While the filing states that the financial statements and the Limited Review Report are enclosed, the detailed numerical tables were omitted from this specific text release. Chemiesynth operates with a small market capitalization of Rs 30 Cr, high debt of Rs 16 Cr, and reported a TTM net loss of Rs -1 Cr.
- Board meeting conducted on November 4, 2026, lasting 50 minutes (2:00 p.m. to 2:50 p.m.)
- Approved unaudited financial results and noted Limited Review Report for period ended September 30, 2026
- Detailed profit and loss numerical tables omitted from the announcement cover extract
Chemiesynth (Vapi) Ltd has approved the allotment of 1,00,00,000 unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) at ₹10 each, raising ₹10 crore in its First Tranche. The fundraise is material relative to the company's size, representing ~100% of its existing net worth (₹10 Cr) and ~33% of its market capitalization (₹30 Cr). The instruments carry a 5% cumulative annual dividend with a 7-year tenure maturing on October 28, 2033, alongside call/put options exercisable after 2 years. The preference shares are unsecured and unlisted, providing non-dilutive capital to equity shareholders.
- Allotment of 1,00,00,000 unlisted NCRPS at ₹10 per share at par
- Total issue size of ₹10,00,00,000 (First Tranche) on a private placement basis
- Carries a 5% cumulative dividend per annum with a 7-year tenure maturing on 28-10-2033
- Company call option and investor put option exercisable after 2 years with 30 days' notice
Chemiesynth (Vapi) Ltd has issued a corrigendum to rectify clerical errors in its board meeting outcome dated August 12, 2026. The share transfer book closure for the 40th Annual General Meeting (AGM) is now scheduled from September 24, 2026, to September 30, 2026. Additionally, the Benpose date for dispatching AGM notices has been moved from August 29 to August 28, 2026. These changes are administrative and do not impact the company's financials or operations.
- Corrected Share Transfer Book Closure period: 24/09/2026 to 30/09/2026
- Revised Benpose Date for AGM notice: 28/08/2026
- Rectification of typographical error in the original filing dated 12/08/2026
- Purpose of the closure is for the 40th Annual General Meeting
Chemiesynth (Vapi) Ltd has approved a significant fundraise of ₹15 crore through the issuance of 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis to promoters or identified persons. This infusion is highly material, representing approximately 62.5% of the company's current market capitalization of ₹24 crore and 150% of its net worth. To accommodate this, the board is seeking shareholder approval to increase the authorized share capital from ₹3.25 crore to ₹18.25 crore. The preference shares carry a 5% cumulative dividend and have a 7-year tenure, providing long-term quasi-equity support to the loss-making entity.
- Proposed issuance of ₹15 crore in 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) to Promoter Group/Identified Persons.
- Authorized share capital to be increased from ₹3.25 crore to ₹18.25 crore, a 461% increase.
- Fundraise amount of ₹15 crore represents approximately 71% of the company's TTM revenue of ₹21 crore.
- NCRPS tenure is fixed at 7 years with a 5% cumulative dividend, payable preferentially over equity shares.
- Both Call and Put options are available after 2 years from the date of allotment.
Chemiesynth (Vapi) Ltd has scheduled a board meeting for August 12, 2026, to approve its Q1 FY27 unaudited financial results. Crucially, the board will also consider a proposal to issue Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) via private placement and an increase in Authorized Share Capital. This follows a fiscal year (FY26) where the company reported a net loss of Rs 0.99 Cr and carries a high Debt-to-Equity ratio of 1.60. Investors should also note the agenda includes approving Related Party Transactions with group companies and promoters.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
- Proposal to issue Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis.
- Plan to increase Authorized Share Capital and amend the Memorandum of Association (MOA).
- Approval of Related Party Transactions with Group Companies and Promoters scheduled for discussion.
- Trading window remains closed from July 01, 2026, until 48 hours after the results declaration.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
